title: Impaired calcium calmodulin kinase signaling and muscle adaptation response in the absence of calpain 3.
abstract: Mutations in the non-lysosomal, cysteine protease calpain 3 (CAPN3) result in the disease limb girdle muscular dystrophy type 2A (LGMD2A). CAPN3 is localized to several subcellular compartments, including triads, where it plays a structural, rather than a proteolytic, role. In the absence of CAPN3, several triad components are reduced, including the major Ca(2+) release channel, ryanodine receptor (RyR). Furthermore, Ca(2+) release upon excitation is impaired in the absence of CAPN3. In the present study, we show that Ca-calmodulin protein kinase II (CaMKII) signaling is compromised in CAPN3 knockout (C3KO) mice. The CaMK pathway has been previously implicated in promoting the slow skeletal muscle phenotype. As expected, the decrease in CaMKII signaling that was observed in the absence of CAPN3 is associated with a reduction in the slow versus fast muscle fiber phenotype. We show that muscles of WT mice subjected to exercise training activate the CaMKII signaling pathway and increase expression of the slow form of myosin; however, muscles of C3KO mice do not exhibit these adaptive changes to exercise. These data strongly suggest that skeletal muscle's adaptive response to functional demand is compromised in the absence of CAPN3. In agreement with our mouse studies, RyR levels were also decreased in biopsies from LGMD2A patients. Moreover, we observed a preferential pathological involvement of slow fibers in LGMD2A biopsies. Thus, impaired CaMKII signaling and, as a result, a weakened muscle adaptation response identify a novel mechanism that may underlie LGMD2A and suggest a pharmacological target that should be explored for therapy.
authors.affiliation: Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.
authors.forename: I
authors.initials: I
authors.lastname: Kramerova
authors.forename: E
authors.initials: E
authors.lastname: Kudryashova
authors.forename: N
authors.initials: N
authors.lastname: Ermolova
authors.forename: A
authors.initials: A
authors.lastname: Saenz
authors.forename: O
authors.initials: O
authors.lastname: Jaka
authors.forename: A
authors.initials: A
authors.lastname: López de Munain
authors.forename: M J
authors.initials: MJ
authors.lastname: Spencer
mesh_terms: D000328:Adult; D000818:Animals; D002118:Calcium / Q000378:metabolism*; D054732:Calcium-Calmodulin-Dependent Protein Kinase Type 2 / Q000235:genetics / Q000378:metabolism*; D002154:Calpain / Q000235:genetics / Q000378:metabolism*; D015536:Down-Regulation; D005260:Female; D006801:Humans; D008297:Male; D051379:Mice; D018345:Mice, Knockout; D008875:Middle Aged; D009124:Muscle Proteins / Q000235:genetics / Q000378:metabolism*; D018482:Muscle, Skeletal / Q000201:enzymology / Q000503:physiopathology*; D049288:Muscular Dystrophies, Limb-Girdle / Q000201:enzymology* / Q000235:genetics / Q000503:physiopathology; D015398:Signal Transduction; D055815:Young Adult
chemical_list: D009124:Muscle Proteins; D054732:Calcium-Calmodulin-Dependent Protein Kinase Type 2; D002154:Calpain; C491373:Capn3 protein, mouse; D002118:Calcium